SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis
In this cohort study of patients with T2D and liver cirrhosis, the use of SGLT2is was associated with substantially lower risks of adverse kidney, cardiovascular, and hepatic outcomes compared with DPP4is. These findings suggested significant cardiorenal and hepatic protection for SGLT2is in this high-risk population.
Authors
- Laing-You Wu
- Ming-Ju Wu
- Chi-Jung Chung
- Mu-Chi Chung
- Jeng-Jer Shieh
- Tung-Min Yu
Institutions
- National Chung Hsing University (TW)
- China Medical University (TW)
- Taichung Veterans General Hospital (TW)
- China Medical University Hospital (TW)
- National Taipei University (TW)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.60429
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Medical University Hospital
- China Medical University
- Division of Materials Research